The phospholipase C-IP3 pathway is involved in muscarinic antinociception

Neuropsychopharmacology

Volumn 28, Issue 5, 2003, Pages 888-897

  Galeotti, Nicoletta ^a   Bartolini, Alessandro ^a   Ghelardini, Carla ^a  

^a Department of Preclinical and Clinical Pharmacology ^*  (Italy)

Author keywords

Analgesia; Ca2+; Inositol l, 4, 5 trisphosphate; Ml muscarinic receptor; Phospholipase C 1; Protein kinase C

Indexed keywords

1 (6 ((3 METHOXYESTRA 1,3,5(10) TRIEN 17 YL)AMINO)HEXYL) 1H PYRROLE 2,5 DIONE; 1-(6-((3-METHOXYESTRA-1,3,5(10)-TRIEN-17-YL)AMINO)HEXYL)-1H-PYRROLE-2,5-DIONE; 2 PYRROLIDONE DERIVATIVE; ANALGESIC AGENT; CHOLINESTERASE INHIBITOR; ESTRANE DERIVATIVE; INOSITOL 1,4,5 TRISPHOSPHATE; MUSCARINIC RECEPTOR; PHOSPHOLIPASE C; PHYSOSTIGMINE;

ANIMAL; ARTICLE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; MALE; METABOLISM; METHODOLOGY; MOUSE; PAIN ASSESSMENT; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANALGESICS; ANIMALS; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRENES; INOSITOL 1,4,5-TRISPHOSPHATE; MALE; MICE; PAIN MEASUREMENT; PHOSPHOLIPASE C; PHYSOSTIGMINE; PYRROLIDINONES; RECEPTORS, MUSCARINIC; SIGNAL TRANSDUCTION;

EID: 0038727260     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300111     Document Type: Article

References (32)

1. Ashkenazi A, Winslow JW, Peralta EG, Peterson GL, Schimerlik MI, Capon DJ (1987). An m2 muscarinic receptor subtype coupled to both adenylyl cyclase and phosphoinositide turnover. Science 238: 672-675.
2. Bartolini A, Ghelardini C, Fantetti L, Malcangio M, Malmberg-Aiello P, Giotti A (1992). Role of muscarinic receptor subtypes in central antinociception. Br J Pharmacol 105: 77-82.
3. Caulfield MP (1993). Muscarinic receptors—characterization, coupling and function. PharmacolTher 58: 319-379.
4. Caulfield MP, Birdsall NJM (1998). International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50: 279-290.
5. Felder CC (1995). Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J 9: 619-625.
6. Ferris CD, Cameron AM, Huganir RL, Snyder SH (1992). Quantal calcium release by purified reconstituted inositol 1, 4, 5-trispho-sphate receptors. Nature 35: 350-352.
7. Ghelardini C, Galeotti N, Bartolini A (2000). Loss of muscarinic antinociception by antisense inhibition of M1 receptors. Br J Pharmacol 129: 1633-1640.
8. Ghelardini C, Galeotti N, Gualtieri F, Romanelli MN, Bartolini A (1996). S-(—)-ET126: a potent and selective Mj antagonist in vivo and in vitro. Life Sci 58: 991-1000.
9. Gillbert PG, GordhJr T, Hartvig P, Jansson I, Petterson J, Post C (1989). Characterization of the antinociception induced by intrathecally administered carbachol. PharmacolToxicol 64: 340-343.
10. Gomeza J, Zhang L, Kostenis E, Felder CC, Bymaster FP, Brodkin J (2001). Generation and pharmacological analysis of M2 and M4 muscarinic receptor knockout mice. Life Sci 68: 2457-2466.
11. Haley TJ, Mccormick WG (1957). Pharmacological effects pro-duced by intracerebral injection of drugs in the conscious mouse. Br J PharmacolChemother 12: 12-15.
12. Hartvig P, Gillberg PG, Gordh T, Post C (1989). Cholinergic mechanisms in pain and analgesia. Trends Pharmacol Sci 1(Suppl.): 75-79.
13. Iwamoto ET, Marion L (1993). Characterization of the antinoci-ception produced by intrathecally administered muscarinic agonists in rats. J PharmacolExpTher 266: 329-338.
14. Jonas S, Sugimori M, Llinas R (1997). Low molecular weight heparin a neuroprotectant? Ann NY AcadSci 825: 389-393.
15. Kennedy ED, Xhalliss RA, Rangan CI, Nahorski SR (1990). Reduced inositol polyphosphate accumulation and inositol supply induced by lithium in stimulated cerebral cortex slices. Biochem J 267: 781-786.
16. Kobayashi E, Nakano H, Morimoto M, Tamaoki T (1989). Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 159: 548-553.
17. Kores B, Lader MH (1997). Irreversible lithium neurotoxicity: an overview. ClinNeuropharmacol 20: 283-299.
18. Malagodi MH, Chiou CY (1974). Pharmacological evaluation of a new Ca++ antagonist, 8-(N, N-diethylamino)-octyl-3, 4, 5-tri-methoxybenzoate hydrochloride (TMB-8): studied in smooth muscle. Eur J Pharmacol 27: 25-33.
19. Mignery GA, Sudhof TC (1990). The ligand binding sites and transduction mechanism in the inositol-1, 4, 5-triphosphate receptor. EMBO J 9: 3893-3898.
20. Naguib M, Yaksh TL (1997). Characterization of muscarinic receptor subtypes that mediate antinociception in the rat spinal cord. AnesthAnalg 85: 847-853.
21. Nishizuka Y (1992). Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258: 607-614.
22. O’Callaghan JP, Holtzman SG (1975). Quantification of the analgesic activity of narcotic antagonists by a modified hotplate procedure. J Pharmacol Exp Ther 192: 497-505.
23. Pellandra CL (1933). La geneserine-morphine adjuvant de l’anesthesiagenerale. Lyon Med 151: 653.
24. Phiel CJ, Klein PS (2001). Molecular targets of lithium action. Annu Rev PharmacolToxicol 41: 789-813.
25. Rebecchi MJ, Pentyala SN (2000). Structure, function and control of phosphoinositide-specific phospholipase C. Physiol Rev 80: 1291-1335.
26. Sanchez-Blazquez P, Garzon J (1998). Delta opioid subtypes activates inositol-signaling pathways in the production of antinociception. J PharmacolExpTher 285: 820-827.
27. Smith SE, Meldrum BS (1992). The protein kinase C activators, phorbol 12-myrystate, 13-acetate and phorbol 12, 13-dibutyrate, are convulsant in the pico-nanomolar range in mice. Eur J Pharmacol 213: 133-135.
28. Taylor SJ, Chae HZ, Rhee SG, Exton JH (1991). Activation of ß1 isozyme of phospholipase C by a subunits of the Gq class of G protein. Nature 350: 516-518.
29. Vaught J, Pelley K, Costa LG, Sether P, Enna SJ (1985). A comparison of the antinociceptive responses to GABA-receptor agonists THIP and baclofen. Neuropharmacology 24: 211-216.
30. Vocci FJ, Welch SP, Dewey WL (1980). Differential effects of divalent cations, cationchelators and ionophore (A23187) on morphine and dibutyrylguanosine 3':5'-cyclic monophosphate antinociception. J PharmacolExpTher 214: 463-466.
31. Wakdo GL, Northup J, Perkins JP, Harden TK (1983). Character-ization of an altered membrane form of the beta-adrenergic receptor produced during agonist-induced desensitization. J Biol Chem 258: 13900-13908.
32. 2+ oscillations in response to cholecystokinin and carbachol but not to JMV-180 in rat pancreatic acinar cells. J BiolChem 267: 13830-13835.